Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Qiagen stock

QGEN
NL0012169213
A2DKCH

Price

43.43
Today +/-
-0.32
Today %
-0.78 %

Qiagen stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Qiagen stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Qiagen stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Qiagen stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Qiagen's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Qiagen Stock Price History

DateQiagen Price
12/5/202443.43 undefined
12/4/202443.77 undefined
12/3/202443.29 undefined
12/2/202443.65 undefined
11/29/202443.43 undefined
11/27/202443.75 undefined
11/26/202443.24 undefined
11/25/202443.25 undefined
11/22/202442.78 undefined
11/21/202442.33 undefined
11/20/202442.09 undefined
11/19/202440.80 undefined
11/18/202440.99 undefined
11/15/202441.27 undefined
11/14/202442.09 undefined
11/13/202442.64 undefined
11/12/202443.23 undefined
11/11/202444.05 undefined
11/8/202443.76 undefined
11/7/202444.15 undefined

Qiagen Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Qiagen, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Qiagen from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Qiagen’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Qiagen. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Qiagen’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Qiagen’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Qiagen’s growth potential.

Qiagen Revenue, EBIT and net profit per share

DateQiagen RevenueQiagen EBITQiagen Net Income
2028e2.71 B undefined870.88 M undefined688.33 M undefined
2027e2.57 B undefined811.44 M undefined626.58 M undefined
2026e2.28 B undefined671.46 M undefined578.14 M undefined
2025e2.14 B undefined604.98 M undefined522.9 M undefined
2024e2.02 B undefined500.02 M undefined495.79 M undefined
20231.97 B undefined445.25 M undefined341.3 M undefined
20222.14 B undefined576.23 M undefined423.21 M undefined
20212.25 B undefined657.85 M undefined512.6 M undefined
20201.87 B undefined537.47 M undefined359.19 M undefined
20191.53 B undefined312.57 M undefined-41.46 M undefined
20181.5 B undefined293.55 M undefined190.38 M undefined
20171.42 B undefined218.46 M undefined40.39 M undefined
20161.34 B undefined166.98 M undefined80.4 M undefined
20151.28 B undefined179.5 M undefined130.15 M undefined
20141.34 B undefined197.92 M undefined116.63 M undefined
20131.3 B undefined63.33 M undefined69.07 M undefined
20121.25 B undefined169.81 M undefined129.51 M undefined
20111.17 B undefined99.59 M undefined96.04 M undefined
20101.09 B undefined188.54 M undefined144.31 M undefined
20091.01 B undefined180.21 M undefined137.77 M undefined
2008892.98 M undefined178.74 M undefined89.03 M undefined
2007649.77 M undefined124.28 M undefined50.12 M undefined
2006465.78 M undefined110.31 M undefined70.54 M undefined
2005398.4 M undefined101.29 M undefined62.23 M undefined
2004380.63 M undefined88.53 M undefined48.71 M undefined

Qiagen Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e
0.010.010.020.020.040.050.070.120.160.220.260.30.350.380.40.470.650.891.011.091.171.251.31.341.281.341.421.51.531.872.252.141.972.022.142.282.572.71
-57.1445.4550.0050.0050.0037.0462.1631.6736.7121.7613.3117.798.264.7416.8339.5737.4413.127.737.547.273.753.31-4.764.455.985.931.6722.5420.37-4.89-8.222.805.696.8412.545.65
71.4363.6468.7566.6775.0072.2272.9768.3370.8969.9169.9667.7966.1066.5868.0968.3966.7267.1566.1165.7864.0765.7162.6466.2964.5364.0265.1466.7665.8665.8864.4264.6462.7561.0457.7554.0648.0345.46
0.010.010.010.020.030.040.050.080.110.150.180.20.230.250.270.320.430.60.670.720.750.820.820.890.830.860.9211.011.231.451.381.2300000
0001258131321342342486270508913714496129691161308040190-41359512423341495522578626688
----100.00150.0060.0062.50-61.5461.90-32.3582.6114.2929.1712.90-28.5778.0053.935.11-33.3334.38-46.5168.1212.07-38.46-50.00375.00-121.58-975.6142.62-17.38-19.3945.165.4510.738.309.90
96.2996.2990.7293.4796.22114.63127.42131.19132.01135.51135.49136.18137.47138.73140.27143.4164.36190.79199.53224.63223.3224.87226.21225.62222.91223.24221.23226.45219.97227.19225.07223.23223.700000
--------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Qiagen Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Qiagen is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (B)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                           
00.010.030.030.030.040.060.080.060.110.230.210.480.350.330.870.930.280.480.330.390.290.440.661.390.750.721.071.421.06
34.686.510.4316.9922.3734.7439.9651.4560.9666.163.5480.43136.71158.44193.74197.42230.77250.73259.71265.23273.85278.24329.14351.61385.12389.06376.21333.52396.92
000.4901.052.225.786.286.248.778.188.447.1525.9920.8835.7317.2233.7246.42124.58237.46182.63142.68432.4870.4899.4997.5593.45100.55118.73
4.226.159.8514.5719.9323.0229.2331.8856.1165.1660.1653.6564.0988.35108.56130.85126.63132.24135.29128.1132.28136.59136.55155.93162.91170.7291.18327.53357.96398.39
1.221.171.663.377.038.2516.620.2422.8218.4526.1137.9248.3947.2782.36107.5988.8472.9675.6978.2121.1278.3140.9272.72176.37161.7131.39247.11183.66175.75
0.010.020.050.060.080.10.150.180.190.260.390.370.680.650.71.331.360.750.990.921.150.961.041.652.161.571.622.112.392.15
7.368.7616.1217.7726.4240.7373.16160.37211.91232.86217.11195.2221.28283.49289.67317.47345.66371.79418.93445.04428.09442.94436.66494.32511.66455.24661.89739.08757.69870.28
0000006.322.760.740.5000000000000041.160.680.74.125.423.520.6
0000000000000000000000014.2000000
000.941.814.598.727.144.8812.7514.5234.7674.57118.49639.11640.31752.3753.33819.49842.6597.68726.91636.42557.16499.32475.04632.43726.19627.44544.8526.82
000000000.030.030.060.090.161.111.151.341.351.731.771.861.891.881.932.012.112.142.362.352.352.48
0.040.150.570.851.534.66.629.3710.515.0719.3931.3628.9196.7599.6856.1798.1459.362.31769.09262.65262.66351.29328.7437.43356.49489294.68215.2374.2
0.010.010.020.020.030.050.090.180.260.290.330.40.532.132.182.462.552.983.13.173.313.223.273.393.593.674.254.043.893.97
0.020.030.070.080.110.150.240.360.450.550.710.771.212.782.893.83.913.734.094.094.454.184.315.045.755.245.876.156.296.12
                                                           
0.230.230.290.290.61.431.451.461.481.491.51.511.542.182.212.712.722.742.772.812.812.812.812.72.72.72.72.72.72.7
0.010.010.040.040.050.060.10.120.130.140.150.160.180.930.961.621.651.671.721.781.821.771.791.631.741.781.831.821.871.92
000.010.020.030.040.060.10.120.160.210.270.340.390.480.620.760.860.991.051.131.211.261.251.381.181.321.792.162.46
1.322.02-1.04-4.48-2.4-4.57-0.4-8.886.5929.9940.6816.9541.2475.0215.1650.1564.7515.943.99-4.19-134.74-259.16-333.68-219.82-310.64-309.62-243.82-326.67-404.09-433.83
0000000000000000000000-0.16-0.94000000
0.010.010.050.050.070.090.170.210.260.330.40.450.571.391.452.292.482.552.752.832.822.722.732.662.812.652.923.293.633.94
1.622.925.556.659.1911.3918.6720.2623.6619.4820.1615.9323.8140.3848.8443.7854.159.8551.3150.8746.1252.3151.2259.2169.4284.77118.15101.2298.7384.16
1.131.763.485.016.719.9314.9718.9524.8527.224148.1559.7795.29151.46232.76178.2183.48152.04182.93163.34128.84144.01173.31209.75332.15220.76219.94215.7210.23
0.31.520.542.854.032.223.1210.1329.739.3518.9320.6725.5427.2934.0945.5876.6960.3658.3798.3189.9286.29112.290.92189.85249.18190.73348.68270.54196.94
001.823.987.5217.797.276.320.9400000000142.33000000000000
0.71.191.351.331.561.672.112.222.349.237.976.927.422.7727.9853.4279.425.625.154.93132.240.9211.36503.18285.2442.54847.63389.55587.97
00.010.010.020.030.040.050.060.080.10.090.090.120.170.260.380.390.450.270.340.430.270.310.320.970.950.571.520.971.08
0.010.010.010.010.010.020.020.080.110.110.210.20.50.980.950.870.80.450.850.851.041.051.071.761.671.421.881.091.470.92
000000.050.55004.1210.3717.5721.71225.89212.59212.69200.67210.37191.61143.76117.2669.6140.6276.7363.4123.4439.2237.5917.512.8
0.070.090.090.140.180.523.364.933.153.594.683.056.018.416.847.0851.463.8858.7538.45206.52224.06284.95337.74406.67303.13580.18401.2357.2293.51
0.010.010.010.010.010.020.030.090.110.120.230.220.531.221.171.131.050.721.11.031.361.341.392.172.141.752.51.531.851.23
0.010.010.020.020.030.060.070.140.190.220.310.310.651.381.431.511.441.171.361.361.81.611.72.53.112.73.073.052.822.31
0.020.030.070.080.110.150.240.360.450.550.710.771.212.772.893.83.913.724.114.24.614.334.435.165.935.355.996.346.456.25
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Qiagen provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Qiagen's financial health and stability.

Assets

Qiagen's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Qiagen must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Qiagen after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Qiagen's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
01258131321342342486270508913714494129691171298040190-41359512423341
011246811152425232121314248142167197199200191213216206231205214208205
010000-1-5-1512-10-25-1-17-10-19-31-22-68-41-36-6660-23-55-6-5-910
-200-4-4-9-6-11-5-14-25-20-3-5-55-18-34-15-42-835-78-2410-87-95-44-72-130-31-186
000003122516-18121396086851376499013180132921213061385174136
0110112114435243036272520173124201820252925212320
000424622131427213614393633416114123422402941421029882
03348122740583664539110184173217250244244259288317341286359330457639715459
-1-1-1-10-7-14-13-41-103-61-22-45-29-35-58-57-69-123-121-128-118-97-117-93-124-150-274-304-206-149-162
-10-1-38-5-12-25-46-90-64-14-51-98-165-659-210-341-215-540-300-251-407-146-179-464-211-222-443-202-726-87
000-2821-11-512-38-5-69-130-601-152-272-91-418-172-133-310-28-85-339-6052-1394-57775
0000000000000000000000000000000
1-1-10201-6623-490-5284440-8-28-50-287251-3224-253-8649396-640-35-41-108-436
010310022042258114218650118-19-60-45-106-253-27628-92036
10-13131414666-195330349412629-35-310226-68192-258-10387360-639-50-150-125-433
0000000000000711263-32-5-4144-8-8-8-61-23-17-17-33
0000000000000000000000000000000
031-3225832-115497-4238-83-144922-607172-6362-102149218501-529-31282-149-62
-1.42.32.2-6.10.7-1.513.5-0.4-45.1-24.641.88.262.266.126.2115.1147.6126.9123.4116.8140.3191200247.7162.4208.755.9153.6432.5566296.65
0000000000000000000000000000000

Qiagen stock margins

The Qiagen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Qiagen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Qiagen.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Qiagen's sales revenue. A higher gross margin percentage indicates that the Qiagen retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Qiagen's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Qiagen's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Qiagen's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Qiagen. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Qiagen's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Qiagen Margin History

Qiagen Gross marginQiagen Profit marginQiagen EBIT marginQiagen Profit margin
2028e62.77 %32.11 %25.38 %
2027e62.77 %31.61 %24.41 %
2026e62.77 %29.44 %25.35 %
2025e62.77 %28.34 %24.49 %
2024e62.77 %24.75 %24.54 %
202362.77 %22.66 %17.37 %
202264.65 %26.91 %19.76 %
202164.43 %29.22 %22.77 %
202065.91 %28.74 %19.2 %
201965.86 %20.48 %-2.72 %
201866.76 %19.55 %12.68 %
201765.18 %15.41 %2.85 %
201664.02 %12.48 %6.01 %
201564.53 %14.01 %10.16 %
201466.28 %14.72 %8.67 %
201362.63 %4.86 %5.31 %
201265.69 %13.54 %10.32 %
201164.1 %8.51 %8.21 %
201065.8 %17.34 %13.27 %
200966.06 %17.85 %13.64 %
200867.16 %20.02 %9.97 %
200766.72 %19.13 %7.71 %
200668.37 %23.68 %15.14 %
200568.24 %25.42 %15.62 %
200466.6 %23.26 %12.8 %

Qiagen Stock Sales Revenue, EBIT, Earnings per Share

The Qiagen earnings per share therefore indicates how much revenue Qiagen has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Qiagen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Qiagen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Qiagen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Qiagen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Qiagen Revenue, EBIT and net profit per share

DateQiagen Sales per ShareQiagen EBIT per shareQiagen Earnings per Share
2028e12.11 undefined0 undefined3.07 undefined
2027e11.46 undefined0 undefined2.8 undefined
2026e10.19 undefined0 undefined2.58 undefined
2025e9.54 undefined0 undefined2.34 undefined
2024e9.02 undefined0 undefined2.21 undefined
20238.79 undefined1.99 undefined1.53 undefined
20229.59 undefined2.58 undefined1.9 undefined
202110 undefined2.92 undefined2.28 undefined
20208.23 undefined2.37 undefined1.58 undefined
20196.94 undefined1.42 undefined-0.19 undefined
20186.63 undefined1.3 undefined0.84 undefined
20176.41 undefined0.99 undefined0.18 undefined
20165.99 undefined0.75 undefined0.36 undefined
20155.75 undefined0.81 undefined0.58 undefined
20145.96 undefined0.88 undefined0.52 undefined
20135.76 undefined0.28 undefined0.31 undefined
20125.58 undefined0.76 undefined0.58 undefined
20115.24 undefined0.45 undefined0.43 undefined
20104.84 undefined0.84 undefined0.64 undefined
20095.06 undefined0.9 undefined0.69 undefined
20084.68 undefined0.94 undefined0.47 undefined
20073.95 undefined0.76 undefined0.3 undefined
20063.25 undefined0.77 undefined0.49 undefined
20052.84 undefined0.72 undefined0.44 undefined
20042.74 undefined0.64 undefined0.35 undefined

Qiagen business model

Qiagen NV is a biotechnology company based in Venlo, Netherlands. The company was founded in 1984 as a spin-off from the University of Düsseldorf and has since become a leading provider of molecular diagnostic products and systems. Qiagen operates in four business areas: Life Sciences, Molecular Diagnostics, Applied Testing, and Pharma. Life Sciences is the largest business area of the company and offers a wide range of products for DNA sequencing, gene expression, RNA isolation and analysis, as well as protein analysis. Molecular Diagnostics specializes in diagnostic tests for diseases such as cancer, infections, and genetic disorders. Applied Testing provides solutions for forensic analysis and food and environmental analysis, while Pharma offers products and services for drug discovery and development. In recent years, Qiagen has focused mainly on the development of molecular diagnostic tests for cancer and infection-related diseases such as HIV, hepatitis, and tuberculosis. These tests enable earlier detection of diseases and more targeted therapy, improving patient care and reducing healthcare costs. One example of a successful Qiagen product is the Cobas HPV Test, a molecular diagnostic test for the detection of human papillomaviruses (HPV) responsible for cervical cancer. The test is distributed by Roche Diagnostics and is one of the best-selling molecular diagnostic tests in the world. Qiagen also has a strong presence in academic research and is a major provider of tools and technologies for DNA sequencing and genome research. Customers include leading research institutes, universities, and pharmaceutical companies. In recent years, Qiagen has also expanded through acquisitions to expand its offering of products and technologies and enter new markets. For example, in 2018, the company acquired N-of-One, a provider of artificial intelligence in cancer diagnostics, and NeuMoDx Molecular, a provider of molecular diagnostic platforms for laboratories. In 2020, Qiagen also played a crucial role in the development of tests for the new coronavirus (SARS-CoV-2). The company, together with other leading diagnostic companies, developed molecular diagnostic tests for rapid and reliable diagnosis of COVID-19. Overall, Qiagen is an important player in the biotech industry, offering a wide range of products and services for molecular diagnostics, genome research, and pharmaceutical research. Qiagen has a strong competitive position due to its innovative products and technologies, strong presence in academic research, and strategic acquisitions to expand its product portfolio and market access. Qiagen is one of the most popular companies on Eulerpool.com.

Qiagen SWOT Analysis

Strengths

1. Established market presence: Qiagen NV has a strong foothold in the global life sciences and diagnostics industry, allowing it to leverage its reputation for quality products and services.

2. Broad product portfolio: Qiagen offers a wide range of innovative solutions for sample technologies, assay technologies, bioinformatics, and automation systems, catering to diverse customer needs.

3. Strong research and development capabilities: The company invests heavily in R&D, enabling it to continually develop and launch new products, staying ahead of competitors and addressing evolving market demands.

Weaknesses

1. Dependence on key customers: Qiagen's growth heavily relies on a few major customers. Any loss of these key accounts could significantly impact the company's financial performance.

2. Limited geographic diversification: While Qiagen operates globally, its business is concentrated in certain regions. This narrow geographic focus exposes the company to potential regional economic, political, or regulatory uncertainties.

3. Product concentration risk: Revenue generation is highly dependent on a few core products. Any decline in demand or competitive pressure for these products could have a negative impact on Qiagen's financials.

Opportunities

1. Expanding molecular diagnostics market: The increasing demand for personalized medicine and advancements in genetic testing provide opportunities for Qiagen to expand its market share in the molecular diagnostics segment.

2. Growing demand for precision medicine: As precision medicine gains traction, Qiagen can further develop targeted therapies and diagnostic solutions, aligning with the trend towards more personalized healthcare.

3. Strategic partnerships and acquisitions: Collaborations with research institutions and strategic acquisitions can help Qiagen expand its product offerings, enhance technological capabilities, and increase its market reach.

Threats

1. Intense competition: The life sciences and diagnostics industry is highly competitive, with numerous players offering similar products and services. Qiagen faces the risk of price wars and the need to continually innovate to maintain its market position.

2. Regulatory challenges: The regulatory environment surrounding the industry can impact the approval process and market entry timelines for Qiagen's products. Adherence to changing regulations and potential delays pose risks.

3. Technological advancements: Rapid technological advancements in the industry may lead to the introduction of more efficient or cost-effective solutions by competitors, potentially rendering Qiagen's existing products less attractive or obsolete.

Qiagen Revenue by Segment

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Qiagen Revenue by Segment

Segmente202320222021
Sample technologies662.99 M USD796.93 M USD850.64 M USD
Diagnostic solutions697.63 M USD660.88 M USD638.76 M USD
PCR / Nucleic acid amplification300.2 M USD390.8 M USD433.97 M USD
Genomics / NGS238.91 M USD224.8 M USD245.07 M USD
Other65.58 M USD68.11 M USD83.22 M USD

Qiagen Revenue by Region

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Qiagen Revenue by Segment

DateAsia Pacific, Japan and Rest of WorldEurope, Middle East and AfricaNetherlandsTotal Americas
2023320.68 M USD624.57 M USD20.3 M USD1.02 B USD
2022410.29 M USD733.47 M USD31.5 M USD997.76 M USD
2021429.86 M USD814.42 M USD28.3 M USD1.01 B USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Qiagen Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Qiagen historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Qiagen shares outstanding

The number of shares was Qiagen in 2023 — This indicates how many shares 223.7 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Qiagen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Qiagen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Qiagen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Qiagen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Qiagen stock splits

In Qiagen's history, there have been no stock splits.

Qiagen dividend history and estimates

In 2023, Qiagen paid a dividend amounting to 0 USD. Dividend means that Qiagen distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Qiagen provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Qiagen’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Qiagen's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Qiagen Dividend History

DateQiagen Dividend
2028e18.45 undefined
2027e16.79 undefined
2026e15.49 undefined
2025e14.01 undefined
2024e13.29 undefined
20171.08 undefined

Qiagen dividend payout ratio

In 2023, Qiagen had a payout ratio of 600%. The payout ratio indicates the percentage of the company's profits that Qiagen distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Qiagen represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Qiagen could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Qiagen's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Qiagen Payout Ratio History

DateQiagen Payout ratio
2028e600 %
2027e600 %
2026e600 %
2025e600 %
2024e600 %
2023600 %
2022600 %
2021600 %
2020600 %
2019600 %
2018600 %
2017600 %
2016600 %
2015600 %
2014600 %
2013600 %
2012600 %
2011600 %
2010600 %
2009600 %
2008600 %
2007600 %
2006600 %
2005600 %
2004600 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Qiagen.

Qiagen latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20240.55 0.57  (3.32 %)2024 Q3
6/30/20240.52 0.55  (5.14 %)2024 Q2
3/31/20240.45 0.46  (2.77 %)2024 Q1
12/31/20230.56 0.55  (-2.22 %)2023 Q4
9/30/20230.51 0.52  (1.43 %)2023 Q3
6/30/20230.53 0.53  (-0.85 %)2023 Q2
3/31/20230.49 0.53  (7.08 %)2023 Q1
12/31/20220.49 0.55  (10.63 %)2022 Q4
9/30/20220.47 0.55  (15.3 %)2022 Q3
6/30/20220.48 0.53  (8.77 %)2022 Q2
1
2
3
4
5
...
12

Eulerpool ESG Scorecard© for the Qiagen stock

Eulerpool World ESG Rating (EESG©)

91/ 100

🌱 Environment

99

👫 Social

99

🏛️ Governance

74

Environment

Scope 1 - Direct Emissions
13,375
Scope 2 - Indirect emissions from purchased energy
19,506
Scope 3 - Indirect emissions within the value chain
334,119
Total CO₂ emissions
32,881
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees50.3
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Qiagen shareholders

%
Name
Stocks
Change
Date
9.88691 % MFS Investment Management22,136,791-59,1616/30/2024
8.57591 % BlackRock Institutional Trust Company, N.A.19,201,46890,43410/25/2024
5.34073 % Wellington Management Company, LLP11,957,9032,450,5716/30/2024
3.91132 % The Vanguard Group, Inc.8,757,450186,0796/30/2024
3.33094 % Capital International Investors7,457,9717,457,9716/30/2024
2.52276 % Amundi Asset Management, SAS5,648,469-2,749,3646/30/2024
2.35440 % Nuance Investments, LLC5,271,494778,0056/30/2024
1.87119 % Norges Bank Investment Management (NBIM)4,189,592-2,340,1656/30/2024
1.81483 % Bank of America Corp4,063,4144,063,4145/10/2024
1.70044 % EARNEST Partners, LLC3,807,284379,6796/30/2024
1
2
3
4
5
...
10

Qiagen Executives and Management Board

Mr. Thierry Bernard

(58)
Qiagen Chief Executive Officer, Managing Director, Member of the Executive Board (since 2020)
Compensation 2.12 M

Mr. Roland Sackers

(54)
Qiagen Managing Director, Chief Financial Officer, Member of the Executive Board
Compensation 1.21 M

Mr. Lawrence Rosen

(66)
Qiagen Independent Chairman of the Supervisory Board (since 2013)
Compensation 194,000

Ms. Elizabeth Tallett

(73)
Qiagen Independent Member of the Supervisory Board
Compensation 101,500

Dr. Metin Colpan

(68)
Qiagen Independent Member of the Supervisory Board (since 1985)
Compensation 86,500
1
2
3

Qiagen Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Ascendis Health Stock
Ascendis Health
SupplierCustomer0,90-0,44-0,37-0,55-0,53-0,45
MDxHealth Stock
MDxHealth
SupplierCustomer0,86-0,320,070,810,260,28
Inovio Pharmaceuticals Stock
Inovio Pharmaceuticals
SupplierCustomer0,740,850,600,890,46-0,18
Invitae Stock
Invitae
SupplierCustomer0,680,880,630,900,390,23
Watts Water Tech A Stock
Watts Water Tech A
SupplierCustomer0,610,460,270,840,800,52
ANGLE Stock
ANGLE
SupplierCustomer0,610,580,220,750,420,26
Sema4 Holdings A Stock
Sema4 Holdings A
SupplierCustomer0,560,860,590,830,19
Thermo Fisher Scientific Stock
Thermo Fisher Scientific
SupplierCustomer0,490,870,560,900,620,53
Altair Engineering A Stock
Altair Engineering A
SupplierCustomer0,460,840,490,880,850,52
Interpace Biosciences Stock
Interpace Biosciences
SupplierCustomer0,240,830,600,810,410,20
1
2

Most common questions regarding Qiagen

What values and corporate philosophy does Qiagen represent?

Qiagen NV represents a strong dedication to innovation, collaboration, and integrity. With a focus on providing cutting-edge solutions for molecular diagnostics and life sciences research, Qiagen NV is committed to improving patient outcomes and advancing healthcare globally. The company's corporate philosophy centers around relentlessly pursuing scientific breakthroughs and enabling scientists and healthcare professionals to make impactful discoveries. By leveraging their expertise in nucleic acid sample preparation and analysis, Qiagen NV aims to empower researchers and clinicians in their quest for improved diagnostics and personalized medicine. Emphasizing excellence, Qiagen NV continues to drive innovation and contribute to the betterment of global health.

In which countries and regions is Qiagen primarily present?

Qiagen NV is primarily present in various countries and regions globally. The company has a significant presence in the United States, Germany, the Netherlands, China, and Switzerland, among others. With its headquarters in Germany, Qiagen NV operates in over 35 countries, serving customers in diverse regions and markets. By focusing on innovative molecular testing solutions, Qiagen NV is committed to improving healthcare outcomes and enabling scientific advancements worldwide.

What significant milestones has the company Qiagen achieved?

Qiagen NV has achieved numerous significant milestones throughout its history. Some of these notable achievements include the development of innovative molecular sample and assay technologies, which have revolutionized the field of life sciences. The company has consistently delivered solutions that enable researchers and scientists worldwide to make groundbreaking discoveries and advancements in genomics, proteomics, and cellular analysis. Qiagen NV has also expanded its global presence by establishing strategic collaborations and partnerships, enhancing its product portfolio, and consistently delivering strong financial performance. These achievements reflect Qiagen NV's dedication to innovation, scientific excellence, and commitment to addressing the evolving needs of its customers in the life sciences industry.

What is the history and background of the company Qiagen?

Qiagen NV is a leading global provider of sample and assay technologies in the field of molecular diagnostics, applied testing, and academic research. Founded in 1984, Qiagen has a rich history of developing innovative solutions for the life sciences industry. The company offers a broad range of products and services including sample preparation, DNA sequencing, and genetic testing. With a strong focus on molecular biology and bioinformatics, Qiagen has established itself as a trusted partner for researchers, healthcare professionals, and pharmaceutical companies worldwide. Over the years, Qiagen has consistently delivered high-quality products, driving advancements in genomics and personalized medicine.

Who are the main competitors of Qiagen in the market?

The main competitors of Qiagen NV in the market are Thermo Fisher Scientific Inc., Illumina Inc., and Becton, Dickinson and Company.

In which industries is Qiagen primarily active?

Qiagen NV is primarily active in the biotechnology and life sciences industries.

What is the business model of Qiagen?

The business model of Qiagen NV focuses on providing innovative solutions for molecular testing and diagnostics. Qiagen NV specializes in sample and assay technologies that enable researchers and healthcare professionals to extract, isolate, and purify nucleic acids from biological samples. They offer a comprehensive portfolio of products and services that cater to various applications, including insights into diseases, personalized healthcare, and forensic analysis. By leveraging their expertise in molecular biology and bioinformatics, Qiagen NV aims to contribute to the advancement of diagnostics, research, and precision medicine.

What is the P/E ratio of Qiagen 2024?

The Qiagen P/E ratio is 19.6.

What is the P/S ratio of Qiagen 2024?

The Qiagen P/S ratio is 4.81.

What is the Quality Investing of Qiagen?

The Quality Investing for Qiagen is 3/10.

What is the revenue of Qiagen 2024?

The expected Qiagen revenue is 2.02 B USD.

How high is the profit of Qiagen 2024?

The expected Qiagen profit is 495.79 M USD.

What is the business model of Qiagen

Qiagen NV is a biotechnology company based in the Netherlands that specializes in the production of medical and laboratory equipment. The company offers a wide range of products and services, including the discovery and validation of biomarkers, the isolation of DNA and RNA, and the performance of gene expression analysis. This article describes the business model of Qiagen NV, including its various divisions and products.

What is the Qiagen dividend?

Qiagen pays a dividend of 0 USD distributed over payouts per year.

How often does Qiagen pay dividends?

The dividend cannot currently be calculated for Qiagen or the company does not pay out a dividend.

What is the Qiagen ISIN?

The ISIN of Qiagen is NL0012169213.

What is the Qiagen WKN?

The WKN of Qiagen is A2DKCH.

What is the Qiagen ticker?

The ticker of Qiagen is QGEN.

How much dividend does Qiagen pay?

Over the past 12 months, Qiagen paid a dividend of 1.08 USD . This corresponds to a dividend yield of about 2.49 %. For the coming 12 months, Qiagen is expected to pay a dividend of 14.01 USD.

What is the dividend yield of Qiagen?

The current dividend yield of Qiagen is 2.49 %.

When does Qiagen pay dividends?

Qiagen pays a quarterly dividend. This is distributed in the months of February, February, February, February.

How secure is the dividend of Qiagen?

Qiagen paid dividends every year for the past 5 years.

What is the dividend of Qiagen?

For the upcoming 12 months, dividends amounting to 14.01 USD are expected. This corresponds to a dividend yield of 32.26 %.

In which sector is Qiagen located?

Qiagen is assigned to the 'Health' sector.

Wann musste ich die Aktien von Qiagen kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Qiagen from 2/1/2024 amounting to 1.32 USD, you needed to have the stock in your portfolio before the ex-date on 1/30/2024.

When did Qiagen pay the last dividend?

The last dividend was paid out on 2/1/2024.

What was the dividend of Qiagen in the year 2023?

In the year 2023, Qiagen distributed 0 USD as dividends.

In which currency does Qiagen pay out the dividend?

The dividends of Qiagen are distributed in USD.

All fundamentals about Qiagen

Our stock analysis for Qiagen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Qiagen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.